摘要
胃癌组织中存在雌激素受体（ＥＲ）已被公认，但贲门癌组织中ＥＲ的存在情况未见报道。本文２３例取材于手术切除的贲门癌标本，采用酶联免疫法和免疫组化法检测ＥＲ。２３例中ＥＲ（＋）１５例（６５．２１％），其中溃疡型占６６．６７％（１０例），略高于ＥＲ（－）（５０．００％）（Ｐ＜０．０５）；淋巴结转移率７３．２４％，明显高于ＥＲ（－）（Ｐ＜０．０１）。作者认为：贲门癌组织中也可存在ＥＲ。ＥＲ（＋）者癌细胞分化较差，淋巴结转移早、快且广泛；贲门癌ＥＲ测定可视为判断预后一个因素；不论是否手术切除的贲门癌，经病理学证实分化差者应常规作ＥＲ测定，对于ＥＲ（＋）者除了应用相应的常规治疗外。
The presence of estrogen receptor in gastrointestinal cancer has been welldocumented, but it has not been reported in cardiac cancer.Cancer tissues from 23 patients with primary cardiac cancer were measured for ER in cytosol by enzyme immunoassay and immunohistochemically. The results showed that 15 out of 23 cases were ERpositive. The frequency of ulcerative cancer in cases positive for ER was 66.67% being slightly greater than that in ER negative patients(62.50%).Of 15 ERpositive cancers 86.67% were poorly differentiated adenocarcinoma which was markedly higher than that in ERnegative patients (50.00%)(P<0.05). The lymph node metastatic rate in ER positive group was 73.24%,significantly higher than that in ERnegatives (35.58%)(P<0.01). The authors found that most of the ERpositive cancers were poorly differentiated adenocarcinoma with early, rapid and extensive involvement of lymph nodes.It is suggested that ER measurement should be done in poorly differentiated cardiac cancers as a predictor of prognosis. Hormonal therapy could be logically considered for the ERpositive patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1998年第1期33-34,共2页
Chinese Journal of Clinical Oncology
关键词
雌激素受体
预后
胃肿瘤
激素疗法
Cardiac cancer Estrogen receptor(ER) Hormonal therapy Prognosis
